June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Clinical characteristics and progression of dry age-related macular degeneration in the Japanese population
Author Affiliations & Notes
  • Yukiko Sato
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Naoko Ueda
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Hideki Koizumi
    Ryukyu Daigaku, Nakagami-gun, Okinawa, Japan
  • Ryo Kawasaki
    Ophthalmology, Osaka Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Suita, Osaka, Japan
  • Maiko Inoue
    Ophthalmology and Micro Technology, Yokohama Shiritsu Daigaku, Yokohama, Kanagawa, Japan
  • Yasuo Yanagi
    Ophthalmology and Micro Technology, Yokohama Shiritsu Daigaku, Yokohama, Kanagawa, Japan
  • Tomohiro Iida
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Kanji Takahashi
    Ophthalmology, Kansai Ika Daigaku, Moriguchi, Osaka, Japan
  • Taiji Sakamoto
    Ophthalmology, Kagoshima Daigaku, Kagoshima, Kagoshima, Japan
  • Akitaka Tsujikawa
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Yukiko Sato None; Naoko Ueda Santen Pharmaceutical, Novartis Pharma, Chugai Pharmaceutical, Code P (Patent); Hideki Koizumi Novartis Pharma, Bayer Yakuhin, Chugai Pharmaceutical、Allegan Japan, Boehringer Ingelheim Japan, Code C (Consultant/Contractor), Novartis Pharma, Alcon Pharma, Alcon Japan, Bayer Yakuhin, HOYA, Senju Pharmaceutical, Santen Pharmaceutical, AMO, Otsuka Pharmaceutical, STAAR Japan, First Medical, Pfizer, KOWA, Nikon, Code F (Financial Support), Novartis Pharma, Alcon Pharma, Bayer Yakuhin, Senju Pharmaceutical, Santen Pharmaceutical, Kowa Pharmaceutical, Alcon Japan, HOYA, AMO, Otsuka Pharmaceutical, Pfizer, Bausch + Lomb Japan、JFC sales plan, Canon, Nidek, Topcon、AbbVie GK, Tomey, Sumitomo Pharma, Chugai Pharmaceutical, Sanofi, Code R (Recipient); Ryo Kawasaki Office future, Nanolux, Code C (Consultant/Contractor), Topcon, Code F (Financial Support), Senju Pharmaceutical, Novartis Pharma, , Bayer Yakuhin, Kowa Pharmaceutical, Santen Pharmaceutical, Alcon Japan, Bausch &Lomb, Nanolux、Tamron, WHILL, Code R (Recipient); Maiko Inoue None; Yasuo Yanagi Roche, Boehringer Ingelheim, Code C (Consultant/Contractor), Alcon Japan, Sanbio, Code F (Financial Support), Chugai, Novartis, Bayer Yakuhin, Santen Pharmaceutical , Boehringer Ingelheim, Senju Pharmaceutical, Roche, Code R (Recipient); Tomohiro Iida Bayer Yakuhin, Novartis Pharma, Chugai Pharmaceutical, Boehringer Ingelheim Japan, Code C (Consultant/Contractor), Nidek, Topcon, Santen Pharmaceutical, Alcon Japan, Novartis Pharma, Senju Pharmaceutical, HOYA, AMO, Pfizer, Otsuka Pharmaceutical, Code F (Financial Support), Topcon, Code P (Patent), Bayer Yakuhin, Novartis Pharma, Alcon Japan, Santen Pharmaceutical, Senju Pharmaceutical, Topcon, Chugai Pharmaceutical, Canon, Nidek, Otsuka Pharmaceutical, Nikon, Code R (Recipient); Kanji Takahashi Novartis Pharma, Santen Pharmaceutical, Kyowa Kirin、Senju Pharmaceutical, Bayer Yakuhin, Code F (Financial Support); Taiji Sakamoto Novartis Pharma, Bayer Yakuhin, Senju Pharmaceutical, Santen Pharmaceutical, Alcon Japan, Chugai Pharmaceutical, Bausch &Lomb, Code F (Financial Support); Akitaka Tsujikawa Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma, HOYA, Ellex, Allegan Japan, Eisai, Daiich-Sankyo, Chugai Pharmaceutical, MSD, Code C (Consultant/Contractor), Canon、Findex、Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Novartis Pharma, Otsuka Pharmaceutical, Bayer Yakuhin, Nitten Pharmaceutical, Code F (Financial Support), Bayer Yakuhin, Senju Pharmaceutical, Novartis Pharma, Santen Pharmaceutical, Alcon Pharma, Alcon Japan, AbbVie GK, AMO Japan, Kowa Pharmaceutical, Canon, Otsuka Pharmaceutical, Wakamoto Pharmaceutical, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2744. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yukiko Sato, Naoko Ueda, Hideki Koizumi, Ryo Kawasaki, Maiko Inoue, Yasuo Yanagi, Tomohiro Iida, Kanji Takahashi, Taiji Sakamoto, Akitaka Tsujikawa; Clinical characteristics and progression of dry age-related macular degeneration in the Japanese population. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2744.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To elucidate the clinical characteristics of dry age-related macular degeneration (AMD) and the progression rate of geographic atrophy (GA) using fundus autofluorescence (FAF) in the Japanese population.

Methods : This is a retrospective multicenter noninterventional study. Consecutive patients with GA secondary to AMD were enrolled from six university hospitals in Japan between January 2009 and December 2021. Only eyes with evaluable FAF images were included. The follow-up group consisted of eyes followed for more than 6 months with FAF images. The GA area was measured semiautomatically on FAF images using the Region Finder software. The GA progression rate was calculated by two methods: mm2/year and mm/year using the square root transformation (SQRT) strategy. Simple and multiple linear regression analyses were used to find baseline factors associated with the GA progression rate.

Results : A total of 173 eyes of 173 patients were included in the study. The mean age was 76.8±8.8 (mean±standard deviation) years, and there was a male predominance (109 men, 63.0%). Mean best-corrected visual acuity was 0.34±0.43 (logarithm of the minimum angle of resolution). Thirty-eight eyes (22.0%) were classified as pachychoroid GA. Sixty-two patients (35.8%) had bilateral dry AMD. The mean GA area was 3.06±4.00 mm2 (1.44±1.00 mm [SQRT]). Central GA and unifocal GA were identified in 90 (52.0%) and 103 (59.5%) eyes, respectively. Soft drusen and reticular pseudodrusen were detected in 115 (66.5%) and 73 (42.2%) eyes, respectively. The mean subfoveal choroidal thickness was 194.7±105.5 µm. In the follow-up group of 101 eyes of 101 patients (mean follow-up period: 46.2±28.9 months), the progression rate of GA was 1.01±1.09 mm2/year (0.23±0.18 mm/year [SQRT]). In multiple linear regression analysis, the GA area [SQRT] (P=0.007) and reticular pseudodrusen (P=0.009) at baseline were significantly associated with the GA progression rate [SQRT].

Conclusions : This study included the largest number of patients with dry AMD in Japan and elucidated the clinical characteristics and GA progression rate. Male predominance, relatively thicker choroid, lower prevalence of drusen and reticular pseudodrusen, and slower GA progression rate were revealed in the Japanese population, compared with Caucasians. A large sized GA and reticular pseudodrusen were associated with fast GA progression.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×